Vanguard Global Advisers
NAGE

Vanguard Global Advisers’s Niagen Bioscience NAGE Stock Holding History

Vanguard Global Advisers’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.7K Hold
22,465
– – ﹤0.01% 2938
2026
Q1 		$99.1K Buy
+22,465
New +$121K ﹤0.01% 2736

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Global Advisers's NAGE Position: Q2 2026 in Review

Vanguard Global Advisers held its Niagen Bioscience (NAGE) position steady in Q2 2026 at 22,465 shares worth $71.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

Vanguard Global Advisers first reported a position in NAGE in Q1 2026 and has held it in 2 quarters since. The position peaked at $99.1K in Q1 2026. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Vanguard Global Advisers held 22,465 shares of Niagen Bioscience worth $71.7K as of Q2 2026.
  • Vanguard Global Advisers left its Niagen Bioscience share count unchanged in Q2 2026.
  • Niagen Bioscience made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2938 holding.
  • Vanguard Global Advisers first reported a position in Niagen Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Niagen Bioscience position peaked at $99.1K in Q1 2026.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.